What is the recommended dose of midostaurin?

Midostaurin, as a drug that has excellent performance in the treatment of acute myeloid leukemia (AML) and systemic mastocytosis (SM), its recommended dose is determined based on the patient's specific condition and the guidance of the doctor. Use of this medication requires strict medical advice to ensure its safety and effectiveness.

For patients with acute myeloid leukemia, the recommended dose of midostaurin is usually 50 mg twice dailytaken with food. This dose is determined when used in combination with induction therapy with cytarabine and daunorubicin or consolidation chemotherapy with high-dose cytarabine. Patients should take midostaurin at this dose on days 8 to 21 of each course of treatment.

For patients with systemic mastocytosis, including aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematologic neoplasm (SM-AHN), or mast cell leukemia (MCL), the recommended dose of midostaurin is different. These patients should take midostaurin twice daily, but the dose is increased to 100 mg each time, again with meals. The setting of this dose is based on the specificity of the condition and the different needs of these patients for drug response.

Importantly, in all patient categories, midostaurin use needs to be continued until disease progression or unacceptable toxicity occurs. At the same time, patients should pay close attention to any possible side effects during medication and report them to their doctors in a timely manner.

In general, the recommended dose of midostaurin is determined based on the patient's specific condition, the type of disease he or she has, and a comprehensive evaluation by the physician. Patients must strictly follow their doctor's instructions when using this medication to ensure optimal treatment and minimize potential risks.